| Literature DB >> 32129004 |
TengDa Qian1,2, Kai Qian1, TuoYe Xu1, Jing Shi1, Tao Ma1,3, ZeWu Song1, ChengMing Xu1, LiXin Li1.
Abstract
INTRODUCTION: Peripheral neurotization, recently as a promising approach, has taken effect in recovering motor function after damage to a peripheral nerve root. Neural anastomosis comprised of nerve conduit and neurorrhaphy participates in the nerve reconstruction. Current literature lacks evidence supporting an individualized coaptation for rescue of locomotor loss in rat subjects with paraplegia secondary to peripheral nerve injury (PNI).Entities:
Keywords: functional recovery; neurotization; neurotube; peripheral nerve injury; personalized coaptation
Mesh:
Year: 2020 PMID: 32129004 PMCID: PMC7177589 DOI: 10.1002/brb3.1582
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Figure 1Flowchart of the literature search
Summary of results included in the meta‐analysis
| Study, publication year | Groups | Gap size (cm) | Male rats (%) | BBB scores | SFI scores | Mean follow‐up (months) |
|---|---|---|---|---|---|---|
| Rodriguez, 2011 | Nerve conduit (20) | 0.5–3.0 (16.80%) | 19 (95%) | 14 (9–15) | 27 (22–34) | 2 |
| Neurorrhaphy (20) | –0.5 (17.85%) | 20 (100%) | 10 (7–13) | 33 (17–56) | 2 | |
| Greene, 2018 | Nerve conduit (17) | 0.5–3.0 (15.88%) | 16 (95.4%) | 13 (9–16) | 40 (22–55) | 3 |
| Neurorrhaphy (17) | ~0.5 (13.81%) | 15 (89%) | 9 (7–14) | 19 (17–20) | 3 | |
| Valero, 2001 | Nerve conduit (6) | 0.5–3.0 (6.100%) | 5 (86%) | 8 (6–12) | 28 (22–39) | 3 |
| Neurorrhaphy (6) | ~0.5 (6.100%) | 6 (100%) | 6 (2–9) | 25 (17–40) | 3 | |
| Wu, 2016 | Nerve conduit (12) | 0.5–3.0 (7.58%) | 11 (92%) | 12 (9–17) | 32 (32–50) | 3 |
| Neurorrhaphy (12) | ~0.5 (10.83%) | 11 (92%) | 9 (8–11) | 35 (19–46) | 3 | |
| Simões, 2010 | Nerve conduit (14) | 0.5–3.0 (12.86%) | 12 (86%) | 11 (9–15) | 37 (28–44) | 3 |
| Neurorrhaphy (14) | ~0.5 (9.64%) | 12 (86%) | 10 (7–12) | 41 (23–60) | 3 | |
| Hamdollah, 2012 | Nerve conduit (30) | 0.5–3.0 (25.83%) | 28 (93%) | 11 (9–12) | 26 (22–38) | 1 |
| Neurorrhaphy (30) | ~0.5 (24.80%) | 28 (93%) | 9 (8–10) | 33 (20–53) | 1 | |
| Wang, 2018 | Nerve conduit (15) | 0.5–3.0 (11.73%) | 15 (100%) | 13 (8–15) | 18 (10–34) | 1 |
| Neurorrhaphy (15) | ~0.5 (12.80%) | 15 (100%) | 14 (9–17) | 26 (17–34) | 1 | |
| D'Arpa S., 2018 | Nerve conduit (20) | 0.5–3.0 (17.85%) | 18 (90%) | 10 (9–13) | 22 (15–29) | 1 |
| Neurorrhaphy (19) | ~0.5 (14.74%) | 16 (84%) | 12 (8–17) | 30 (14–38) | 1 | |
| Cemil B., 2009 | Nerve conduit (10) | 0.5–3.0 (10.100%) | 10 (100%) | 7 (3–15) | n.r. | 2 |
| Neurorrhaphy (10) | ~0.5 (10.100%) | 9 (90%) | 10 (5–16) | n.r. | 2 | |
| Youlai, 2015 | Nerve conduit (16) | 0.5–3.0 (15.95%) | 13 (87%) | 11 (8–15) | 52 (46–63) | 3 |
| Neurorrhaphy (16) | ~0.5 (16.100%) | 15 (95%) | 10 (9–16) | 33 (22–47) | 3 | |
| García, 2014 | Nerve conduit (6) | 0.5–3.0 (6.100%) | 5 (83%) | 8 (3–10) | n.r. | 3 |
| Neurorrhaphy (6) | ~0.5 (6.100%) | 4 (67%) | 10 (8–13) | n.r. | 3 | |
| Nadi M., 2015 | Nerve conduit (9) | 0.5–3.0 (6.67%) | 8 (89%) | 11 (8–14) | 27 (22–34) | 2 |
| Neurorrhaphy (9) | ~0.5 (8.89%) | 9 (100%) | 13 (9–16) | 33 (19–41) | 2 |
ARR and OR calculating with the corresponding 95% CI for good functional outcome following neurotization
| Variables | Follow‐up | Functional outcome | Number of subjects | ARR (95%) |
| OR (95%) |
|
|
|---|---|---|---|---|---|---|---|---|
| Nerve conduit Subjects in all types of defect | 1‐month follow‐up | BBB > 9 | 79 | 15% (12%, 20%) | .0006 | 0.10 (0.05,0.40) | .003 | .62 |
| SFI = 0 | 98 | 23% (19%, 28%) | <.001 | 0.14 (0.04, 0.47) | <.0001 | .48 | ||
| 2‐month follow‐up | BBB > 9 | 115 | 7% (−2%, 11%) | .001 | 0.17 (0.08, 0.30) | .004 | .81 | |
| SFI = 0 | 52 | 18% (13%, 21%) | <.002 | 0.21 (0.10, 0.31) | .0001 | .72 | ||
| 3‐month follow‐up | BBB > 9 | 126 | 3% (−5%, 6%) | .027 | 1.67 (1.34, 2.30) | <.0001 | .51 | |
| SFI = 0 | 34 | 12% (9%, 17%) | <.001 | 0.38 (0.20, 0.73) | .17 | .64 | ||
| Small nerve defect (<0.5 cm) | 2‐month follow‐up | BBB > 9 | 47 | 16% (11%, 22%) | <.001 | 0.09 (0.03, 0.38) | .003 | .27 |
| SFI = 0 | 38 | 19% (15%, 23%) | .0015 | 1.91 (1.20, 3.87) | <.0001 | .76 | ||
| Medium nerve defect (0.5–3.0 cm) | 2‐month follow‐up | BBB > 9 | 56 | 18% (13%, 27%) | .057 | 0.68 (0.21, 2.27) | .002 | .34 |
| SFI = 0 | 31 | 10% (9%, 16%) | <.001 | 0.14 (0.06, 0.35) | .0034 | .36 | ||
| Neurorrhaphy | ||||||||
| Small nerve defect (<0.5 cm) | 2‐month follow‐up | BBB > 9 | 50 | 17% (14%, 19%) | .0048 | 1.28 (0.91, 1.73) | <.0001 | .2 |
| SFI = 0 | 28 | 11% (7%, 18%) | <.001 | 0.20 (0.12, 0.35) | .27 | .08 | ||
| Medium nerve defect (0.5–3.0 cm) | 2‐month follow‐up | BBB > 9 | 63 | 35% (30%, 43%) | .00012 | 0.16 (0.02, 1.10) | .06 | .07 |
| SFI = 0 | 46 | 24% (21%, 38%) | <.001 | 0.33 (0.21, 0.47) | .64 | .21 | ||
Modified Newcastle–Ottawa Quality Assessment Scale (cohort studies)
| Assessment of quality of a cohort study—Newcastle–Ottawa scale | |
|---|---|
| Selection (tick one box in each section) | |
| 1. Representativeness of the intervention cohort | |
| (a) Truly representative of the HCH‐caused hemiplegia population | * |
| (b) Somewhat representative of the HCH‐caused hemiplegia population | * |
| (c) Selected group of participants | |
| (d) No description of the derivation of the cohort | |
| 2. Selection of the nonintervention cohort | |
| (a) Drawn from the same community as the intervention cohort | * |
| (b) Drawn from a different source | |
| (c) No description of the derivation of the nonintervention cohort | |
| 3. Ascertainment of intervention | |
| (a) Secure record (e.g., healthcare record) | * |
| (b) Structured interview | * |
| (c) Written self report | |
| (d) Other/no description | |
| 4. Demonstration that outcome of interest was not present at start of study | |
| (a) Yes | * |
| (b) No | |
| Comparability (tick one or all boxes, as appropriate) | |
| 1. Comparability of cohorts on the basis of the design or analysis | |
| (a) Study controls for nerve defects | * |
| (b) Study controls for BBB: Basso, Beattie, and Bresnahan for locomotor functional recovery | * |
| Outcome (tick one box in each section) | |
| 1. Assessment of outcome | |
| (a) Independent blind assessment | * |
| (b) Record linkage | * |
| (c) Self report | |
| (d) Other/no description | |
| 2. Was follow‐up long enough for outcomes to occur | |
| (a) Yes, if median duration of follow‐up ≥2 months | * |
| (b) No, if median duration of follow‐up <2 months | |
| 3. Adequacy of follow‐up of cohorts | |
| (a) Complete follow‐up: all subjects accounted for | * |
| (b) Subjects lost to follow‐up unlikely to introduce bias: number lost <= 20%, or description of those lost suggesting no different from those followed | * |
| (c) Follow‐up rate <80% (select an adequate %) and no description of those lost | |
| (d) No statement |
A study can be awarded a maximum of one star for each numbered item within the selection and outcome categories. A maximum of two stars can be given for comparability.
Risk of bias assessment for nonrandomized cohort studies (modified Newcastle–Ottawa scale)
| First author, year | Selection | Comparability | Outcome | Total score |
|---|---|---|---|---|
| Rodriguez, 2011 | ** | *** | ** | 7/9 |
| Greene, 2018 | ** | ** | ** | 6/9 |
| Valero, 2001 | ** | ** | *** | 7/9 |
| Wu, 2016 | ** | *** | ** | 7/9 |
| Simões, 2010 | *** | * | ** | 6/9 |
| Hamdollah, 2012 | ** | ** | *** | 7/9 |
| Wang, 2018 | *** | ** | ** | 7/9 |
| Nadi M., 2015 | * | *** | *** | 7/9 |
| D'Arpa S., 2018 | ** | *** | ** | 7/9 |
Figure 2Risk of bias assessment for randomized controlled trials. “+”, low risk of bias; “−”, high risk of bias; and “?”, indicates unclear risk of bias
Figure 3Forest plot with OR estimating with the corresponding 95% CI for favorable outcome (defined as BBB ≥ 9) associated with nerve conduit versus neurorrhaphy for individual trials and the pooled population at 1‐month, 2‐month, and 3‐month follow‐ups (subjects in all gaps). CI, confidence interval; BBB, Basso, Beattie, and Bresnahan for locomotor functional recovery; OR, odds ratio
Figure 4Forest plot with OR estimating with the corresponding 95% CI for (a) favorable outcome (defined as BBB ≥ 9 and SFI ≥ 40) associated with nerve conduit versus neurorrhaphy individual trials and the subgroup population stratified by size of defect for 2‐month follow‐up (b). CI, confidence interval; BBB, Basso, Beattie, and Bresnahan for locomotor functional recovery; OR, odds ratio
Figure 5Forest plot with OR estimating with the corresponding 95% CI for the proportion of rats with poor outcome in motor function (defined as BBB < 9 or SFI < 40) associated with nerve conduit versus neurorrhaphy for individual trials and the pooled population at 1‐month, 2‐month, and 3‐month follow‐ups (rats in all defects). CI, confidence interval; BBB, Basso, Beattie, and Bresnahan for locomotor functional recovery; OR, odds ratio; SFI, sciatic functional index
Figure 6Funnel plot to detect publication bias. No significant funnel asymmetry was observed which could indicate publication bias (p‐value for Egger test was .27). logOR, Natural logarithm of the OR; SE of logOR, standard error of the logOR